Home » Market News » DirectorsTalk Highlights » WideCells Group PLC presentation on stem cell technology in São Paulo, Brazil
WideCells Group PLC

WideCells Group PLC presentation on stem cell technology in São Paulo, Brazil

WideCells Group PLC LON:WDC the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, has this morning told DirectorsTalk about its attendance at the Obstetrics and Gynaecology Conference in São Paulo, Brazil, 25-26 May 2017. At the conference, Dr Niranjan Bhattacharya, a preeminent figure in the stem cell industry and founding member of CellPlan’s Stem Cell Panel, will be making a presentation on stem cell technology and the developments both he and WideCells are driving within the industry.

Dr Bhattacharya’s expansive career in medical research focuses on cell and tissue therapy in degenerative disease and placental umbilical cord blood. He is currently the Head of the Department and Chair Professor of the Department of Regenerative Medicine and Translational Science, and is Director General of the Public Cord Blood Bank and Calcutta School of Tropical Medicine in Kolkata, India. Alongside this, he is a senior consultant in Obstetrics and Gynaecology and General Surgery in a number of premier private hospitals in Kolkata, India. Furthermore, as a founding member of the Stem Cell Panel, he is responsible for reviewing patient cases for CellPlan, the Company’s innovative stem cell insurance product, providing and managing a panel of expert doctors who provide secondary medical opinion to WideCells/CellPlan patients, and ultimately helping to ensure that the Company’s competitive service offering and insurance policy remains fully reflective of industry developments.

For further information on the conference please visit http://www.sogesp.com.br/eventos/xi-jornada-de-obstetricia-e-ginecologia-de-campinas-e-regiao-e-xi-encontro-dos-ex-residentes


Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.